Sernova Corp (DE:PSH0)
XETRA:PSH0
PSH0 Stock Chart & Stats
€0.11
--
Market closed
€0.11
--
Day’s Range― - ―
52-Week Range€0.06 - €0.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.46K
Market Cap
€31.09M
Enterprise Value€50.08M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€2.45M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Sep 10, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding347,726,350
10 Day Avg. Volume5,531
30 Day Avg. Volume4,462
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€186.75K
Bulls Say, Bears Say
Bulls Say
Proprietary Cell Pouch PlatformSernova's Cell Pouch System is a durable platform advantage: an implantable device that creates a vascularized tissue environment to sustain therapeutic cells (eg, insulin-producing cells). As a device+cell combination it is extensible across chronic diseases and supports differentiated clinical/ commercial pathways.
Clinical-stage DevelopmentBeing clinical-stage reduces the translational gap versus preclinical peers and creates definable regulatory and clinical milestones that can materially de-risk the business. Focus on chronic conditions like insulin-dependent diabetes aligns the platform with a large, persistent addressable market.
Improving Loss And Burn TrendsManagement has meaningfully reduced cash burn and narrowed losses across 2023–2025 and into the TTM period, indicating better cost control and operational discipline. Those durable margin improvements extend runway and lower near-term financing frequency if sustained alongside clinical progress.
Bears Say
Pre-revenue With Persistent LossesThe company reports no revenue across provided periods and continues to record operating losses and negative free cash flow. This structural lack of revenue means the business is dependent on financing or partnerships to support operations until commercialization, raising long-term execution risk.
Deteriorated Balance Sheet; Negative EquityStockholders' equity turning negative and a marked decline in assets materially weaken financial flexibility. Negative equity constrains access to traditional debt, increases refinancing and counterparty risk, and can complicate collaborations or licensing deals that require demonstrable balance-sheet strength.
Ongoing Cash Burn Requires External FundingDespite improved burn rates, the company reported negative operating and free cash flow across all periods, implying continued dependency on equity/debt raises or partners to fund R&D and trials. Recurrent financing needs risk dilution and can delay development timelines if capital markets tighten.
Sernova News
PSH0 FAQ
What was Sernova Corp’s price range in the past 12 months?
Sernova Corp lowest stock price was €0.06 and its highest was €0.20 in the past 12 months.
What is Sernova Corp’s market cap?
Sernova Corp’s market cap is €31.09M.
When is Sernova Corp’s upcoming earnings report date?
Sernova Corp’s upcoming earnings report date is Sep 10, 2026 which is in 85 days.
How were Sernova Corp’s earnings last quarter?
Sernova Corp released its earnings results on Jun 11, 2026. The company reported -€0.006 earnings per share for the quarter, the consensus estimate of -€0.006 by €0.
Is Sernova Corp overvalued?
According to Wall Street analysts Sernova Corp’s price is currently Overvalued.
Does Sernova Corp pay dividends?
Sernova Corp does not currently pay dividends.
What is Sernova Corp’s EPS estimate?
Sernova Corp’s EPS estimate is 0.
How many shares outstanding does Sernova Corp have?
Sernova Corp has 347,726,350 shares outstanding.
What happened to Sernova Corp’s price movement after its last earnings report?
Sernova Corp reported an EPS of -€0.006 in its last earnings report, expectations of -€0.006. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sernova Corp?
Currently, no hedge funds are holding shares in DE:PSH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sernova Corp
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms for localized cellular immune protection. The Cell Pouch itself is an innovative medical device engineered to establish a highly vascularized tissue environment, crucial for the successful transplantation and engraftment of therapeutic cells. Once integrated, these cells are designed to secrete vital proteins or hormones, providing sustained treatment for a range of severe chronic conditions, including diabetes, hemophilia, and thyroid dysfunction. To bolster its research and development, Sernova maintains a collaborative partnership with AgeX Therapeutics, Inc. focused on generating immune-protected therapeutic cells, and an ongoing research agreement with the University of Miami to further refine its Cell Pouch cell therapy platform. Established in 1998, Sernova Corp. maintains its corporate headquarters in London, Canada.
Technical Analysis
Covalon Technologies
―
Microbix Biosystms
―
Medmira
―
NurExone Biologic
―
Defence Therapeutics
―
Options Prices
Currently, No data available
---